IE83226B1 - An adduct containing clarithromycin and ranitidine - Google Patents
An adduct containing clarithromycin and ranitidineInfo
- Publication number
- IE83226B1 IE83226B1 IE2000/0248A IE20000248A IE83226B1 IE 83226 B1 IE83226 B1 IE 83226B1 IE 2000/0248 A IE2000/0248 A IE 2000/0248A IE 20000248 A IE20000248 A IE 20000248A IE 83226 B1 IE83226 B1 IE 83226B1
- Authority
- IE
- Ireland
- Prior art keywords
- ranitidine
- adduct
- clarithromycin
- hydrate
- containing clarithromycin
- Prior art date
Links
- 229960000620 Ranitidine Drugs 0.000 title claims description 32
- VMXUWOKSQNHOCA-LCYFTJDESA-N Ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 title claims description 32
- 229960002626 clarithromycin Drugs 0.000 title claims description 21
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 title claims description 21
- 239000000203 mixture Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 9
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000003208 petroleum Substances 0.000 claims description 3
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000003115 biocidal Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 3
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 3
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 3
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 3
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 3
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940079866 intestinal antibiotics Drugs 0.000 description 3
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 3
- 206010019375 Helicobacter infection Diseases 0.000 description 2
- 241000191938 Micrococcus luteus Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- XAUTYMZTJWXZHZ-IGUOPLJTSA-K bismuth;(E)-1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 XAUTYMZTJWXZHZ-IGUOPLJTSA-K 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000001586 eradicative Effects 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960004696 ranitidine bismuth citrate Drugs 0.000 description 2
- -1 carbapenems Chemical class 0.000 description 1
- 229940041011 Carbapenems Drugs 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229940040944 Tetracyclines Drugs 0.000 description 1
- 238000009632 agar plate Methods 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 150000001622 bismuth compounds Chemical class 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 201000000432 peptic ulcer disease Diseases 0.000 description 1
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Inorganic materials [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005429 turbidity Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/552—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being an antibiotic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Description
AN ADDUCT CONTAINING CLARITHROMYCIN AND RANITIDINE
Introduction
Ranitidine is a H2-receptor antagonist of formula (I):
It inhibits the gastric acid secretion and is widely used in the treatment of
gastrointestinal disorders. For the eradication of Helicobacter pylori infections,
which are closely related to peptic ulcer diseases, bismuth compounds such as
Ranitidine bismuth citrate are commonly administered.
A combination therapy comprising Ranitidine and antibacterial agents is also
generally accepted. The activity of Ranitidine, especially against Helicobacter
organisms, can be significantly increased by co-administration of antibiotics. A
variety of antibiotics are suitable for this purpose, e.g. tetracyclines, penicillins,
carbapenems, cephalosporins, aminoglycosides or macrolide antibiotics.
Clarithromycin appears to show in combination with Ranitidine higher
eradication rates regarding Helicobacter infections than any other antibiotic
(Arzneim.-Forsch. 45(2), 184-186 [1995]).
European patent application EP 533 281 describes the use of Ranitidine bismuth
citrate in combination with various types of antibiotics for the treatment or
prevention of gastrointestinal disorders. The individual components may be co-
administered in separate or single compositions.
While such combination products are useful, it is generally difficult to provide
such combination products in acceptable formulations. One of the problems with
*‘ 83226
combined therapies is one of patient compliance, especially when different
quantities or numbers of the individual elements are to be administered.
This invention is directed towards providing a novel presentation for such
combination products which will overcome at least some of these problems.
Statements of Invention
The invention provides novel pharmaceutically active and stable adducts
containing Clarithromycin and Ranitidine or a hydrate thereof wherein the molar
ratio of Clarithromycin to Ranitidine in the adduct is at least 2:1.
The preferred H2-receptor antagonist is Ranitidine which is preferably introduced
as the base hydrate.
The ratios may be integers or non—integers.
The invention also provides a process for the preparation of an adduct of the
invention in which Clarithromycin and Ranitidine are reacted in an organic or
aqueous solvent. Preferably the reaction temperature is from 20°C to 25°C.
Ideally, the solvent is petroleum ether.
The invention further provides the use of the adducts of the invention for the
treatment of gastrointestinal disorders.
In addition, the invention provides a pharmaceutical formulation including an
adduct of the invention.
Detailed description of the invention
It has surprisingly been found that Ranitidine can be bound to Clarithromycin by
formation of adducts. This feature is of significance for the preparation of novel
combination products, especially for the treatment of gastrointestinal disorders.
The Ranitidine can be administered simultaneously with the Clarithromycin in
one unit. The ratio of Ranitidine to Clarithromycin can be readily varied, as
required. The formed adducts may be readily used for final product formulations,
e.g. for the manufacture of tablets or capsules. No pre-mixing of the individual
components is required.
It has been observed that the Ranitidine is especially suitable to form adducts with
Clarithromycin. Ranitidine may be used conveniently as the base without
converting it into a pharmaceutically acceptable and stable salt prior to the
formation of the adduct.
Ranitidine may be reacted with Clarithromycin to produce novel adducts which
are of high stability. The adducts are antibiotically active and suitable for the
treatment of gastrointestinal disorders.
Adducts prepared from Ranitidine base hydrate and Clarithromycin were found
to be of particular interest. Ranitidine base hydrate is described in detail in our
WO-A-99/ 65890 the entire contents of which are incorporated herein by
reference. Such adducts can be obtained via a very simple process in high quality
and quantitative yield under very mild reaction conditions.
The novel adducts may be conveniently formulated, e.g. preferably into orally
administerable medicaments such as tablets or capsules. Those skilled in the art
can decide which excipients, carriers, solvents, fillers, lubricants, techniques and
quantities are employed in the formulation process.
The invention will be more clearly understood from the following example.
Preparation of a Clarithromvcin-Ranitidine-12:1] adduct
.50 kg (3.33 mol) of Clarithromycin and 640 g (1.67 mol) of Ranitidine base
hydrate are suspended in approximately 7-8 1 of a suitable solvent such as
petroleum ether. The mixture is agitated preferably at room temperature for
several hours. The product is filtered off, washed with some solvent and dried
under vacuum, optionally at elevated temperature. A quantitative yield is typically
obtained.
Analytical data:
Mp.: 210.4—211.9°C.
FT-IR (KBr): 9 [cm1] = 3488, 2978, 2940, 1733, 1691, 1458, 1379, 1171, 1107,
1051, 1011 (Figure 1).
Powder X-ray peaks of medium and high intensity:
C1arithromycin—Ranitidine [2:1]: 20 = 8.81, 9.75, 11.04, 11.68, 13.98, 15.35,
16.69, 17.06, 17.45, 18.27, 19.27, 20.04, 20.67, 22.36 (Figure 2).
Clarithromycinz 20 = 5.09, 6.80, 9.42, 10.38, 10.65, 12.11, 12.37, 13.99, 14.32,
.48, 16.47, 19.11, 21.41, 23.11, 23.93 (Figure 3).
Ranitidine: 20 = 8.91, 16.19, 17.21, 17.74, 19.94, 22.30, 25.66, 26.09, 28.04
(Figure 4).
Antibiotic Activity
Micrococcus luteus from stock was streaked on a nutrient agar plate to confirm
colony morpbiology, colour and purity. After 24 hours incubation at 37°C an
isolated colony is picked and inoculated into 10 ml of nutrient broth. This is
incubated overnight at 37°C and is subsequently used as the inoculum.
l0 mg of each of the test compounds is weighed and dissolved in 10 ml of analar
methanol in sterile 20 ml universal containers. This is then diluted with ringers
buffer solution to give a concentration of 1 mg/ ml.
Quantitation of activity is determined using an MIC (Mean Inhibitory
Concentration) liquid tube assay. For each test substance the following
concentrations are set up: 10 ug/ml, 5 ug/ml, 1 ug/ml, 0.5 ug/ml, 0.l ug/ml,
0.05 ug/rnl and 0.01 ug/ml. Each contained nutrient broth and 0.1 ml of
overnight culture of Micrococcus luteus.
The tubes were incubated at 37°C and observed for growth after 24 hours and 48
hours. Growth is assessed by dense turbidity, optical density at 660 nm using a
spectrophotometer or clarity. The MIC is the last concentration where growth
inhibited.
The following table gives the MIC values for the compounds examined:
Compound MIC lug/rnll
Clarithromycin S 0.01
Clarithromycin-Ranitidine [2:l] S 0.01
Ranitidine Base Hydrate no significant antibiotic activity
The invention is not limited to the embodiments hereinbefore described which
may be varied in detail.
Claims (1)
- CLAIMS An adduct containing Clarithromycin and Ranitidine or a hydrate thereof wherein the molar ratio of Clarithromycin to Ranitidine in the adduct is at least 2:1. An adduct as claimed in claim 1 wherein the Ranitidine is present in the form of Ranitidine base. An adduct as claimed in claim 1 wherein the Ranitidine is present in the form of Ranitidine base hydrate. An adduct substantially as hereinbefore described with reference to the examples. A process for the preparation of an adduct as claimed in any preceding claim wherein Clarithromycin and Ranitidine or a hydrate thereof are reacted in an organic or aqueous solvent. A process as claimed in claim 5 wherein the reaction temperature is from 20°C to 25°C. A process as claimed in any of claims 5 to 6 wherein the organic solvent is petroleum ether. A process for the preparation of an adduct substantially as hereinbefore described with reference to the examples. An adduct containing Clarithromycin and Ranitidine or a hydrate thereof whenever prepared by a process as claimed in any of claims 5 to 8. Use of an adduct containing Clarithromycin and Ranitidine or a hydrate thereof for the treatment of gastrointestinal disorders. Use as claimed in claim 10 wherein the adduct is as claimed in any of claims 1 to 4 or 9. A pharmaceutical formulation including an adduct containing Clarithromycin and Ranitidine or a hydrate thereof wherein the molar ratio of Clarithromycin to Ranitidine in the adduct is at least 2:1. A formulation as claimed in claim 12 wherein the adduct is as claimed in any of claims 1 to 4 or 9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE2000/0248A IE83226B1 (en) | 2000-04-04 | An adduct containing clarithromycin and ranitidine |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IEIRELAND29/04/199919990357 | |||
| IE990357 | 1999-04-29 | ||
| IE990993 | 1999-11-29 | ||
| IE2000/0248A IE83226B1 (en) | 2000-04-04 | An adduct containing clarithromycin and ranitidine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE20000248A1 IE20000248A1 (en) | 2000-11-29 |
| IE83226B1 true IE83226B1 (en) | 2004-01-14 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1071331C (en) | Anti-helicobacter acyl derivatives of azolones | |
| SK79599A3 (en) | 8-cyano-1-cyclopropyl-6-fluoro-7-(2-oxa-5,8- -diazabicyclo[4.3.0]non-8-yl)-1,4-dihydro-4-oxo-3-quinolone carboxylic acid, the use thereof and medicaments comprising the same | |
| HU196221B (en) | Process for production of acetil-eritromicin-stearat and medical preparatives containing - as reagent - such compounds | |
| UA105775C2 (en) | Rifamycin derivatives | |
| US6413969B1 (en) | Gatifloxacin pentahydrate | |
| FR2470134A1 (en) | NOVEL ANTIBIOTICS, THEIR PREPARATION AND THEIR USE | |
| US6077830A (en) | Bismuth salts of antibiotics of the moenomycin group, processes for their preparation, their use and pharmaceuticals comprising such salts | |
| CN107641119B (en) | Monocycle beta-lactam-siderophore conjugates and its preparation method and application | |
| CN103030684B (en) | Novel bleomycin analogue as well as preparation method and application thereof | |
| EP0787494B1 (en) | Use of rifamycin derivatives for the manufacture of a medicament for the treatment of diseases caused by infections of helicobacter pylori | |
| IE83226B1 (en) | An adduct containing clarithromycin and ranitidine | |
| HU205932B (en) | Process for producing triacetate derivative of bu-3420t antibioticum and pharmaceutical compositions containing them | |
| US9862680B2 (en) | Peripherally substituted monocyclic beta-lactams | |
| IE20000248A1 (en) | An adduct containing Clarithromycin and Ranitidine | |
| US6599885B2 (en) | Derivatives of erythromycin, clarithromycin, roxithromycin or azithromycin with antibiotic and mucolytic activity | |
| KR20000016544A (en) | Improved process for preparing potassium clavulanate | |
| EP0076066B1 (en) | Penicillin derivatives | |
| CN115160276B (en) | Pyrylium salt compound and preparation method and application thereof | |
| EP0369503B1 (en) | Method for the control of pneumocystis carinii | |
| AU626576B2 (en) | Crystalline (5r,6s)-2-carbamoyloxymethyl-6-{(1r)- hydroxyethyl}-2-penem-carboxylic acid and its pharmaceutical formulation | |
| EP0861660B9 (en) | Curative medicine for disease caused by infection of Helicobacter | |
| GB2088864A (en) | Doxycycline monosodium tetrametaphosphate complexes and their preparation | |
| BE886301A (en) | NOVEL ANTIBIOTICS, THEIR PREPARATION AND THEIR USE | |
| JP2001019656A (en) | BENZ[a]ANTHRACENE-1,7,12-TRIONE DERIVATIVE | |
| JPH10218888A (en) | Organobismuth derivative |